Lymphoma

H 8701; CD34-selection for ex vivo T-cell Depletion of Mobilized Peripheral Blood Stem Cells for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Receiving Intensive Conditioning: This study uses a monoclonal antibody and high dose chemotherapy and radiotherapy combined with haploidentical allogeneic stem cell transplantation to treat pediatric patients with hematologic malignancies. 

H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H: This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.

H12472; Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients with Hematological Diseases: This study uses monoclonal antibodies and low dose chemotherapy and radiotherapy combined with allogeneic stem cell transplantation to treat patients with hematologic malignancies who also have other complications such as kidney, liver, or heart disease.

H12870: Phase I/II Study of anti-Human CD45 monoclonal Antibodies in Patients with Advanced Leukemia prior to Allogeneic Stem Cell Transplantation:  This study uses monoclonal antibodies and high dose chemotherapy and radiotherapy combined with autologous stem cell transplantation to treat patients with hematologic malignancies.

H17529: A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors – BMT CTN Protocol 0201:  This study compares outcomes for patients receiving allogeneic (unrelated) stem cell transplant following high dose chemotherapy (and in some cases radiation therapy). The two groups being compared are patients whose stem cell product comes from donor bone marrow or patients whose stem cell product comes from donor peripheral blood stem cells.

LYMPHOMA (including CLL)  

H 8701; CD34-selection for ex vivo T-cell depletion of mobilized peripheral blood stem cells for recipients of HLA haploidentical related donor stem cell grafts receiving intensive conditioning: This study uses a monoclonal antibody and high dose chemotherapy and radiotherapy combined with haploidentical allogeneic stem cell transplantation to treat pediatric patients with hematologic malignancies.

H8713; Phase I/II Study of Allogeneic Stem Cell Transplantation for Patients with Hematologic Malignancy, Using Haploidentical Family Donors and Sub-Myeloablative Conditioning with Campath 1H: This study uses a monoclonal antibody, low dose chemotherapy and radiation combined with haploidentical allogeneic stem cell transplantation to treat patients with hematologic malignancies who have already received a stem cell transplant or who also have other complications such as kidney, liver, or heart disease.

H9936; Administration Of LMP Specific Cytotoxic T-Lymphocytes To Patients With Relapsed EBV-Positive Hodgkin Disease: This study uses autologous EBV specific T-Lymphocytes targeting the EBV proteins LMP1 and LMP2 to treat lymphoma.

H11541: Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) with Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells: This study uses autologous gene modified tumor cells (also referred to as a vaccine) which release IL-2 and CD40L to treat patients with CLL. 

H11967: Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) with Human IL-2 and CD40 Ligand Plasmid Gene Modified Autologous Tumor Cells: This study uses autologous gene modified tumor cells (also referred to as a vaccine) which release  IL-2 and CD40L to treat patients with CLL. 

H12472; Phase I/II Study of CD45 Antibodies and Alemtuzumab Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients with Hematological Diseases: This study uses monoclonal antibodies and low dose chemotherapy and radiotherapy combined with allogeneic stem cell transplantation.

H11892; A Current Practice Study Of Rituxan In Patients Receiving BEAM Chemotherapy And Autologous Blood Stem Cell Transplantation For High Risk Lymphoma And Hodgkin's Disease: This study uses a monoclonal antibody and high dose chemotherapy combined with autologous stem cell transplantation.

H14424; Administration of EBV-specific Cytotoxic T Lymphocytes Following CD45 Antibody to Patients with Relapsed EBV Positive Hodgkin’s or Non-Hodgkin’s Lymphoma: This study uses a monoclonal antibody and EBV specific T-Lymphocytes to treat lymphoma.

H17656: Treatment of Chronic Lymphocytic B-Leukemia (B-CLL) with Human IL-2 Gene Modified and Human CD40 Ligand-Expressing Autologous Tumor Cells after Depletion of Regulatory T Cells: This study uses a combination of monoclonal antibodies and autologous gene modified tumor cells (also referred to as a vaccine) which release  IL-2 and CD40L to treat patients with CLL. 

H17946: Administration of TGF-b Resistant LMP-Specific Cytotoxic T-Lymphocytes to Patients with Relapsed EBV-Positive Lymphoma: This study uses EBV specific T-Lymphocytes with a gene inserted to render them resistant to TGF-b to treat lymphoma.

H19275: Administration of LMP1- AND LMP2-specific Cytotoxic T-Lymphocytes following CD45 Antibody to Patients with Relapsed EBV-Positive Hodgkin’s or non-Hodgkin’s Lymphoma: This study uses a combination of monoclonal antibodies and  autologous EBV specific T-Lymphocytes to treat lymphoma.

H19747: Prolonged Immunisation with Autologous CD40 Ligand and IL-2-expressing Tumor Cells for Treatment of B-Chronic Lymphocytic Leukemia (B-CLL): This study uses autologous gene modified tumor cells (also referred to as a vaccine) which release  IL-2 and CD40L to treat patients with CLL given over a longer period of time than other studies listed above. 

©2002, Cell And Gene Therapy, Baylor College of Medicine
One Baylor Plaza, N1002, Houston, TX 77030, (713)798-1246
URL: http://www.bcm.edu/genetherapy Email:cagt@bcm.edu
(Modified: September 21st, 2007 - jb)